SCHEMBL5154664

SCHEMBL5154664

O=C(NN1CCCCC1)c1cc(-c2ccc(Br)cc2)n(-c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 11/20 0.88
CNR2 P34972 6/20 0.63
ABCC4 O15439 1/20 0.57
MLNR O43193 1/20 0.57
ABCB11 O95342 1/20 0.57
CHRM2 P08172 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CYP2C9 P11712 1/20 0.57
ADRA2B P18089 1/20 0.57
ADRA2C P18825 1/20 0.57
DRD1 P21728 1/20 0.57
TBXA2R P21731 1/20 0.57
SLC6A2 P23975 1/20 0.57
HRH2 P25021 1/20 0.57
HTR2A P28223 1/20 0.57
AGTR1 P30556 1/20 0.57
CCKAR P32238 1/20 0.57
CCKBR P32239 1/20 0.57
MC4R P32245 1/20 0.57
ABCC1 P33527 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157539 0.94 CNR1 (1.00) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4613969 0.91 CNR1 (0.90) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL14155480 0.87 CNR1 (0.83) CNR1CNR2
SCHEMBL14155477 0.86 CNR1 (0.81) CNR1CNR2RPA1
SCHEMBL3087783 0.81 CNR1 (0.73) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL3816611 0.81 CNR1 (0.71) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL5157006 0.81 RPA1 (0.85) CNR1RPA1
SCHEMBL674910 0.80 CNR1 (0.60) CNR1RPA1
SCHEMBL3087784 0.80 CNR1 (0.71) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL2118655 0.80 CNR1 (1.00) CNR1CNR2ABCC4MLNRABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007017125-A1 CB1 ANTAGONISTS OR INVERSE ANTAGONISTS AS THERAPEUTICAL AGENTS FOR THE TREATMENT OF INFLAMMATION INVOLVING GENE EXPRESSION LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-15 WO claimed
EP-1752149-A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-14 EP claimed
WO-2007009701-A2 USE OF SUBSTITUTED PYRAZOLE COMPOUNDS AND COMBINATIONS THEREOF FOR THE TREATMENT OF THE METABOLIC SYNDROME LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO claimed
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1752149-A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-14 EP disclosed
WO-2007009701-A2 USE OF SUBSTITUTED PYRAZOLE COMPOUNDS AND COMBINATIONS THEREOF FOR THE TREATMENT OF THE METABOLIC SYNDROME LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO disclosed
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed